Skip to main content
Explainer5 min readDraft, not yet medically reviewed

What recruiting status means in a clinical trial registry

Recruiting status means a study is listed as seeking participants. It does not mean a site is active, that international patients are accepted, or that a person meets protocol criteria.

Updated 2026-09-11. For: Patients and families reading study listings

Diagram perjalanan EGFR: mutasi, terapi target, progresi, mekanisme resistensi, pemeriksaan ulang, opsi berikutnya

This is not news and not a medical review

Explains registry status without discussing a specific study code.

Medical review status

This is a standing explainer, not breaking news and not a medical review. It has not been reviewed by a doctor and does not replace the explanation of the medical team caring for the patient. Not a diagnosis or final medical recommendation. Requires physician review.

One registry fact, not three

A registry records the status of a study overall. It does not fully describe whether each site is ready or whether patients from another country are accepted.

What recruiting does not guarantee

Important details sit outside the registry status.

  • Readiness and activity of each study site.
  • International patient acceptance and conditions.
  • Whether a person fits inclusion and exclusion criteria.
  • How costs are split between the study and participant.
Diagram perjalanan EGFR: mutasi, terapi target, progresi, mekanisme resistensi, pemeriksaan ulang, opsi berikutnya

Penjelasan visual

The EGFR journey after targeted therapy stops working

The sequence usually discussed when EGFR-targeted therapy no longer controls the disease. It covers tests and questions, not drug recommendations.

This diagram explains the sequence of assessment and discussion. It is not treatment advice or an eligibility decision.

Read the EGFR marker explainer
  1. An EGFR alteration is found

    Recorded in the molecular report, not only in its conclusion.

  2. Targeted therapy is given

    Including the start date, dose, and reason for changing treatment when relevant.

  3. The disease progresses

    Assessed from imaging and the clinical condition by the treating doctor.

  4. Possible resistance mechanisms

    For example C797S, MET, or another alteration that may be found on repeat testing.

  5. Repeat testing or NGS

    Determines which changes are actually present in this case.

  6. Discuss the next step

    Reviewed with the doctor according to the patient's condition and available options.

When targeted therapy stops working, it does not automatically mean there are no further options to discuss.

Next step

If a study looks relevant, review the criteria and confirm access directly with the study team or site. The clinical trial guide explains the difference between registry, site, and international access status.

Note about this explainer

This is a standing explainer for understanding a term, not news about a specific study.

Ilustrasi hangat konsultasi pasien dengan tenaga medis melalui telepon

Langkah berikutnya

If this question relates to your condition, build a structured case summary so your questions and documents are ready to discuss with a doctor.

Next steps

These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.

What you can do

  • Upload medical reports

    Build a case summary in twelve steps

    Reason: Often the most useful next step after reading this page

  • Request a second opinion

    Review of the treatment plan

    Reason: Relevant when a treatment plan is being considered

  • Consult a navigator

    A request is recorded with this page context

    Reason: For asking the next step directly

Recently updated

Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.

Prepare for your next consultation

Use the free six-question tool to prepare questions for your doctor.